<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Emerging Infect. Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24274068</article-id>
      <article-id pub-id-type="pmc">3840850</article-id>
      <article-id pub-id-type="publisher-id">13-0521</article-id>
      <article-id pub-id-type="doi">10.3201/eid1912.130521</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
        <subj-group subj-group-type="article-type">
          <subject>Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hepatitis E and Lymphocytic Leukemia in Man, Italy</article-title>
        <alt-title alt-title-type="running-head">Hepatitis E and Lymphocytic Leukemia in Man, Italy</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Giordani</surname>
            <given-names>Maria T.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fabris</surname>
            <given-names>Paolo</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brunetti</surname>
            <given-names>Enrico</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goblirsch</surname>
            <given-names>Sam</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roman&#xF2;</surname>
            <given-names>Luisa</given-names>
          </name>
        </contrib>
        <aff id="aff1">San Bortolo Hospital, Vicenza, Italy (M.T. Giordani, P. Fabris); University of Pavia, Pavia, Italy (E. Brunetti); </aff>
        <aff id="aff2">Winona Health, Winona, Minnesota, USA (S. Goblirsch); </aff>
        <aff id="aff3">University of Milan, Milan, Italy (L. Roman&#xF2;)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Maria T. Giordani, Department of Infectious and Tropical Disease, San Bortolo Hospital, Via Rodolfi 37, Vicenza 36100, Italy; email: <email xlink:href="giordanimt@gmail.com">giordanimt@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2013</year>
      </pub-date>
      <volume>19</volume>
      <issue>12</issue>
      <fpage>2054</fpage>
      <lpage>2056</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>hepatitis E</kwd>
        <kwd>hepatitis</kwd>
        <kwd>hepatitis E virus</kwd>
        <kwd>HEV</kwd>
        <kwd>viruses</kwd>
        <kwd>lymphocytic leukemia</kwd>
        <kwd>immunocompromised patient</kwd>
        <kwd>ribavirin</kwd>
        <kwd>antiviral agents</kwd>
        <kwd>human</kwd>
        <kwd>chronic disease</kwd>
        <kwd>Italy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor:</bold> Hepatitis E is an enterically transmitted infection with worldwide distribution and high prevalence in developing countries. This disease can occur as large water-borne epidemics associated with hepatitis E virus (HEV) genotypes 1 and 2. Hepatitis E is less common in industrialized countries, including Italy (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>), where sporadic autochthonous cases associated with genotypes 3 and 4 have been reported. Virus strains of these genotypes are widespread in different mammalian species, including wild boar (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>).</p>
    <p>We report a case of hepatitis E in a 60-year-old man born and living in Vicenza, Italy, who was admitted to the Emergency Department of Vicenza Hospital on May 9, 2012 with symptoms of acute icteric hepatitis. He had been given a diagnosis of chronic lymphocytic leukemia and hemolytic anemia in 2003 and underwent 8 treatment cycles of cyclophosphamide and steroids, which were completed 20 days before he came to the Emergency Department.</p>
    <p>His liver function test results at admission were the following: alanine aminotransferase 1,804 IU/L, total bilirubin 24.1 mg/dL, and alkaline phosphatase 137 IU/L. Test results for other causes of viral hepatitis were negative (<xref ref-type="fig" rid="F1">Figure</xref>). A liver biopsy performed on June 1 showed severe acute lobular hepatitis with necrosis and cholestasis. Serum obtained at admission was positive for IgM and IgG against HEV (Dia.Pro Test, Milan, Italy). </p>
    <fig id="F1" fig-type="figure" position="float">
      <label>Figure</label>
      <caption>
        <p>Clinical and laboratory data for a 60-year-old man with hepatitis E and lymphocytic leukemia, Italy, 2012. Start of ribavirin treatment and virologic response are indicated. A differential diagnosis was obtained by using abdominal ultrasound, which showed an enlarged hypoechogenic liver and thickening of the gallbladder wall (5 mm) with gallstones in the lumen, but a regular biliary tree. An enlarged spleen (bipolar diameter 15.07 cm) and lymph nodes were attributed to chronic lymphocytic leukemia. Test results for the following markers were negative: viral hepatitis A, B, and C; hepatitis B virus DNA (nested PCR; Roche, Switzerland); hepatitis C virus (nested PCR; Roche); cytomegalovirus virus DNA; Epstein-Barr virus; Q fever; agglutination for <italic>Leptospira</italic> spp. (Galton's test); enteric fever; <italic>Borrelia</italic> spp.; <italic>Bartonella</italic> spp.; autoantibodies (anti-nuclear, anti&#x2013;liver kidney microsomal, anti-mitochondrial); blood and feces cultures; and ova and parasites in feces. HEV, hepatitis E virus; NA, not available; AST, aspartate aminotransferase; ALT, alanine aminotransferase. Reference ranges were 8&#x2013;48 IU/L for AST, 7&#x2013;55 IU/L for ALT, and 0.1&#x2013;1.0 mg/dL for total bilirubin.</p>
      </caption>
      <graphic xlink:href="13-0521-F"/>
    </fig>
    <p>HEV RNA was detected by reverse transcription PCR and open reading frame 2 (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>) was detected in serum and feces samples on May 9. Phylogenetic analysis of sequences identified HEV genotype 3 subtype h in serum and fecal samples (GenBank accession nos. KC782933 and KC782934).</p>
    <p>Three months after admission, the patient had viremia, and results of liver function tests were abnormal. Recent data suggest that immunosuppressed persons who are viremic 3 months after HEV infection do not spontaneously clear HEV (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>). Therefore, the patient was given antiviral therapy to achieve viral clearance. Ribavirin, 1,000 mg/day in 2 doses (400 and 600 mg), was administered during August 2&#x2013;November 2, 2012. This drug was well tolerated, although the patient experienced mild anemia (hemoglobin level 10.5 mg/dL), which did not require any treatment.</p>
    <p>Liver function test results returned to reference levels on day 14 of treatment. HEV RNA was detected in blood and feces on day 18 of treatment (August 20). Viral clearance (HEV absent from feces and serum) was achieved on day 54 of treatment (September 27) and was sustained over a 6-month period after the end of therapy.</p>
    <p>The source of the HEV infection was uncertain. The patient had never traveled outside Italy. However, he had butchered a wild boar that he had hunted in Barberino del Mugello (Tuscany) in March 2012. The patient&#x2019;s wife, who also butchered the animal, was positive for IgG against HEV but negative for IgM against HEV and for HEV RNA in February 2013. No boar meat was available for HEV testing, which indicated that this route of transmission was likely, but not confirmed.</p>
    <p>Autochthonous hepatitis E in industrialized countries is usually an acute, self-limiting disease, but chronic disease can occur in immunocompromised hosts (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>). These hosts include transplant recipients, persons infected with HIV, and patients with hematologic malignancies. Chronic infection with HEV has only been documented with genotype 3 strains and has been observed in many countries in Europe, However, to our knowledge, no cases of chronic infection with HEV have been reported in Italy. Our results indicate that chronic infection with HEV genotype 3 occurs in Italy.</p>
    <p>Acute and chronic hepatitis E have been reported in patients with hematologic malignancies. An autochthonous case of acute hepatitis E was recently described in Germany in a patient with chronic lymphocytic leukemia that had been treated with chemotherapy, a bone marrow transplantation, and hemodialysis (<xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). He did not receive any specific treatment for hepatitis E and died of acute liver failure 39 days after diagnosis. Reactivation of hepatitis E in a patient with acute lymphoblastic leukemia was reported after allogeneic stem cell transplantation (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>). HEV can also be transmitted directly from an infected transplanted organ.</p>
    <p>Ribavirin monotherapy is an effective treatment for most patients with chronic HEV infection (<xref ref-type="bibr" rid="R8"><italic>8</italic></xref>). It has also been used successfully to treat acute severe infection by genotype 1 of HEV in developing countries and by genotype 3 in industrialized countries (<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>), and is used to treat hepatitis C, although its mechanism of action against HCV and HEV is uncertain. Data are limited on the use of ribavirin in patients with chronic hepatitis E and hematologic malignancies (<xref ref-type="bibr" rid="R10"><italic>10</italic></xref>). The outcome for our patient suggests that ribavirin might be useful for treating hepatitis E in such patients.</p>
    <p>In conclusion, all patients with hepatitis of unknown origin should be tested for HEV, in particular, immunocompromised patients, because they are at risk of acquiring chronic hepatitis and having an adverse outcome. Ribavirin appears to be efficacious in treating hepatitis E and should be considered for any immunocompromised person who has viremia 3 months after acute infection.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Giordani MT, Fabris P, Brunetti E, Goblirsch S, Roman&#xF2; L. Hepatitis E and lymphocytic leukemia in man, Italy [letter]. Emerg Infect Dis [Internet]. 2013 Dec [<italic>date cited</italic>]. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3201/eid1912.130521">http://dx.doi.org/10.3201/eid1912.130521</ext-link></p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Alessandro Zanetti for reviewing the article and Antonio Perasole for valuable support with histologic analysis.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Roman&#xF2;</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Paladini</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tagliacarne</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Canuti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bianchi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zanetti</surname>
<given-names>AR</given-names></string-name>. <article-title>Hepatitis E in Italy: a long-term prospective study.</article-title>
<source>J Hepatol</source>. <year>2011</year>;<volume>54</volume>:<fpage>34</fpage>&#x2013;<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.jhep.2010.06.017</pub-id><pub-id pub-id-type="pmid">20888660</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Martelli</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Caprioli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Zengarini</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Marata</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Fiegna</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Di Bartolo</surname>
<given-names>I</given-names></string-name>, <etal/>
<article-title>Detection of hepatitis E virus (HEV) in a demographic managed wild boar (<italic>Sus scrofa scrofa</italic>) population in Italy.</article-title>
<source>Vet Microbiol</source>. <year>2008</year>;<volume>126</volume>:<fpage>74</fpage>&#x2013;<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.vetmic.2007.07.004</pub-id><pub-id pub-id-type="pmid">17706898</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Emerson</surname>
<given-names>SU</given-names></string-name>, <string-name><surname>Nguyen</surname>
<given-names>HT</given-names></string-name>, <string-name><surname>Torian</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Mather</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Firth</surname>
<given-names>AE</given-names></string-name>. <article-title>An essential RNA element resides in a central region of hepatitis E virus ORF2.</article-title>
<source>J Gen Virol</source>. <year>2013</year>;<volume>94</volume>:<fpage>1468</fpage>&#x2013;<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1099/vir.0.051870-0</pub-id><pub-id pub-id-type="pmid">23515023</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Kamar</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Rostaing</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Legrand-Abranevel</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Izopet</surname>
<given-names>J</given-names></string-name>. <article-title>How should hepatitis E infection be defined in organ transplant recipients?</article-title>
<source>Am J Transplant</source>. <year>2013</year>;<volume>13</volume>:<fpage>1935</fpage>&#x2013;<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1111/ajt.12253</pub-id><pub-id pub-id-type="pmid">23659713</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Kamar</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bendall</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Legrand-Abravanel</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Xia</surname>
<given-names>NS</given-names></string-name>, <string-name><surname>Ijaz</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Izopet</surname>
<given-names>J</given-names></string-name>, <etal/>
<article-title>Hepatitis E.</article-title>
<source>Lancet</source>. <year>2012</year>;<volume>379</volume>:<fpage>2477</fpage>&#x2013;<lpage>88</lpage> . <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61849-7</pub-id><pub-id pub-id-type="pmid">22549046</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Pfefferle</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Frickmann</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Gabriel</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Schmitz</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Gunther</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Schmidt-Chanasit</surname>
<given-names>J</given-names></string-name>. <article-title>Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany.</article-title>
<source>Infection</source>. <year>2012</year>;<volume>40</volume>:<fpage>451</fpage>&#x2013;<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1007/s15010-011-0220-7</pub-id><pub-id pub-id-type="pmid">22086667</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>le Coutre</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Meisel</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hofmann</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rocken</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Vuong</surname>
<given-names>GL</given-names></string-name>, <string-name><surname>Neuburger</surname>
<given-names>S</given-names></string-name>, <etal/>
<article-title>Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation.</article-title>
<source>Gut</source>. <year>2009</year>;<volume>58</volume>:<fpage>699</fpage>&#x2013;<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1136/gut.2008.165571</pub-id><pub-id pub-id-type="pmid">19359434</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Gerolami</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Borentain</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Raissouni</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Motte</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Solas</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Colson</surname>
<given-names>P</given-names></string-name>. <article-title>Treatment of severe acute hepatitis E by ribavirin.</article-title>
<source>J Clin Virol</source>. <year>2011</year>;<volume>52</volume>:<fpage>60</fpage>&#x2013;<lpage>2</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcv.2011.06.004</pub-id><pub-id pub-id-type="pmid">21764632</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Mallet</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Nicand</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Sultanik</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Chakvetadze</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Tess&#xE9;</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Thervet</surname>
<given-names>E</given-names></string-name>, <etal/>
<article-title>Case reports of ribavirin treatment for chronic hepatitis E.</article-title>
<source>Ann Intern Med</source>. <year>2010</year>;<volume>153</volume>:<fpage>85</fpage>&#x2013;<lpage>9</lpage>
<pub-id pub-id-type="doi">10.7326/0003-4819-153-2-201007200-00257</pub-id><pub-id pub-id-type="pmid">20547886</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Alric</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Bonnet</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Beynes-Rauzy</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Izopet</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kamar</surname>
<given-names>N</given-names></string-name>. <article-title>Definitive clearance of a chronic hepatitis E virus infection with ribavirin treatment.</article-title>
<source>Am J Gastroenterol</source>. <year>2011</year>;<volume>106</volume>:<fpage>1562</fpage>&#x2013;<lpage>3</lpage>
<pub-id pub-id-type="doi">10.1038/ajg.2011.158</pub-id><pub-id pub-id-type="pmid">21811285</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
